查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197798

寡核甘酸合成市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Oligonucleotide Synthesis Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计寡核甘酸合成市场在预测期内的复合年增长率为 12.3%。

COVID-19 正在影响寡核甘酸合成市场的增长。 反过来，对 COVID-19 诊断的需求不断增长，也增加了全球对构成分子诊断产品基础的寡核甘酸原材料的需求。 2022 年 3 月在 PLOS One 上发表的一项研究证实，该寡核甘酸成功靶向冠状病毒基因组中的 5'-polyU。 此外，开发具有基本突变靶点（如 5'-polyU）的 COVID-19 疗法可以减少新型 SARS-CoV-2 的产生和传播。 此类研究正在影响药物开发中寡核甘酸的需求和采用，影响大流行期间的市场增长。

此外，多家公司正在投资寡核甘酸合成，预计这将在预测期内推动市场增长。 例如，2021 年 9 月，SpeeDx 将投资本地寡核甘酸製造，以降低供应链风险并开发更重要的关键诊断主权能力。 预计这些发展将增加寡核甘酸在药物开发中的采用，预计将在预测期内推动市场增长。

其他重要因素包括增加政府对製药和生物技术公司的投资和研发支出，以及合成寡核甘酸在分子诊断和临床应用中的使用。

政府越来越多地资助各种基因组学项目，以开发治疗多种慢性和罕见疾病的先进疗法。 预计这将增加对用于药物开发的寡核甘酸的需求，从而推动市场增长。 例如，2022 年 9 月，美国国立卫生研究院投资超过 6 亿美元，开始下一阶段的人类大脑基因组计划。 这笔资金将帮助设计新的方法，将治疗药物和其他分子靶向特定的脑细胞群。

此外，企业和政府为促进基于寡核甘酸的药物的开发以及寡核甘酸技术在製药和生物技术行业的采用而采取的举措不断增加，预计也将推动市场增长。 例如，2021 年 2 月，CPI 在药品製造创新中心启动了一个项目，以彻底改变寡核甘酸的製造。 药品製造创新中心已启动与阿斯利康、Exactmer、诺华和英国研究与创新公司的合作，以开发可扩展、可持续和更具成本效益的寡核甘酸（合成 DNA 或 RNA 的短链）药品製造过程。 这一发展有望提高这种令人兴奋的新型药物的生产能力和生存能力，从而在预测期内推动市场增长率。

此外，在分子诊断和临床应用中越来越多地采用寡核甘酸也有助于市场增长。 例如，2022 年 2 月，伊利诺伊大学厄巴纳分校的研究人员开发了一种用于癌症检测的新型 miRNA 即时检验。 该测试使用纳米粒子捕获人血清中的肿瘤特异性 microRNA (miRNA)。 2021 年 1 月，Diagenode 推出了一种新的小 RNA 测序解决方案 D-Plex Small RNA DNBSEQ Kit，与 MGI 的 DNBSEQ 测序仪兼容。 该试剂盒以极低的 RNA 输入量展示了高性能，并且可以使用专有的 D-Plex 技术通过文库製备来检测各种小 RNA 转录本。

因此，研发和设施开发正在取得进展，预计研究目标市场将在预测期内扩大。 然而，寡核甘酸的高加工成本、缺乏熟练的专业人员以及欠发达国家的研究支持预计将在预测期内阻碍寡核甘酸合成市场的增长。

寡核甘酸合成市场趋势

治疗药物板块有望保持高CAGR

由于慢性病和罕见病患病率增加、药物开发中越来越多地采用寡核甘酸以及产品发布增加等因素，预计在预测期内，治疗领域的寡核甘酸合成市场将出现显着增长。

寡核甘酸疗法是一类使用反义寡核甘酸或小干扰 RNA (siRNA) 靶向 RNA 或蛋白质的疗法。 寡核甘酸疗法包括靶向转录因子以阻断转录的诱饵，调节与特定 mRNA 互补的 microRNA (miRNA) 的表达，并限制特定蛋白质从 mRNA 的翻译。 例如，根据 2022 年 2 月发表在 Future Medicine 上的一篇文章，寡核甘酸疗法是创造罕见疾病治疗方法的最具适应性的平台之一。

此外，成长型公司努力采用各种业务战略，例如合作伙伴关係和融资，也有助于市场增长。 例如，2022 年 1 月，Ceptur Therapeutics, Inc. 宣布将基于其专有的 U1 接头技术开发 RNA 疗法，这是一种结合序列特异性 mRNA 和 U1 微核核糖核蛋白的二价寡核甘酸。成功筹集了 7500 万美元的资金由 venBio Partners 和美国启明创投领投的 A 轮融资。 U1 小核核糖核蛋白是一种控制转录和剪接的细胞内机器。 通过利用与 U1 snRNP 相互作用的合成寡核甘酸，可以利用该转录因子高度靶向和调节 mRNA。

此外，越来越多的产品发布和批准预计将增加对寡核甘酸药物的需求，从而推动市场增长。 例如，2021 年 2 月，美国食品和药物管理局批准 Amondis 45 (Kazimersen) 注射液用于治疗 DMD 基因已确认突变的杜氏肌营养不良症 (DMD) 患者。

此外，多家公司正在开发寡核甘酸疗法，预计这将增加製药和生物技术行业的采用率，从而促进市场增长。 例如，根据 clinicaltrials.gov 的数据，截至 2022 年 7 月，TME Therapeutics 正在开发 STNM01，该药物正在 I 期临床试验中进行评估，以治疗无法切除的胰腺癌。 Nitto BioPharma 还在开发 ND-L02-s0201，该药物正在特发性肺纤维化 (IPF) 的 II 期试验中进行评估。

因此，由于企业活动增加、采用各种商业策略进行基于寡核甘酸的药物开发和新产品发布等因素，预计该细分市场将在预测期内增长。.

预计北美将占所研究市场的很大份额

北美预计将在预测期内主导市场。 市场增长的驱动因素包括慢性病和罕见病在人口中的患病率上升、公司研发支出的增加以及该地区主要市场参与者的存在。

根据 Cancer Facts and Figures 2022，预计 2022 年美国将诊断出超过 190 万新癌症患者。 此外，根据Breastcancer.org公布的2022年统计数据，2022年美国估计将有287,850例浸润性乳腺癌新发病例和51,400例原位乳腺癌新发病例。 人口中日益增加的癌症负担推动了对先进疗法的需求，推动了对寡核甘酸疗法的需求并推动了市场增长。

根据 IDF 发布的 2022 年统计数据，到 2021 年，加拿大约有 290 万人患有糖尿病。 到 2030 年，这一数字预计将达到 320 万，到 2045 年将达到 340 万。 由于预计该国糖尿病患者人数将增加，因此在抗糖尿病药物的开发中，对能够在 RNA 和蛋白质水平上抑制致病基因表达的反义寡核甘酸的需求将增加。 预计这将在预测期内推动市场增长。

按地区增加药物开发和增加产品发布预计将推动市场增长。 例如，2022年1月，美国食品和药物管理局发布了一项针对杂合子家族性高胆固醇血症（HeFH）或临床动脉粥样硬化性心脏病（ASCVD）的新建议，需要额外降低低密度脂蛋白胆固醇（LDL-C）。获得包涵体注射液（Leqvio）的批准)，一种创新的低增量硅烷 RNA 药物，用于成人饮食和他汀类药物治疗。

此外，根据 clinicaltrials.gov，截至 2022 年 7 月，TME Pharma Agis 正在对微卫星稳定的转移性胰腺癌患者进行 Olaptesed Pegol (NOX-A12) 联合派姆单抗和纳米脂质体伊立替康/5-FU。A II 期亚叶酸或吉西他滨/nab-紫杉醇的组合正在进行临床试验。

此外，公司增加投资以增加生产和扩大寡核甘酸药物的设施也有助于市场增长。 例如，2021 年 3 月，Nitto Denko Corporation 将向其美国子公司 Nitto Denko Avecia Inc. 投资约 250 亿日元（2.27 亿美元），以提高其治疗性寡核甘酸业务的製造能力。

在北美，由于癌症增加、产品发布和批准增加、企业开展临床试验的活动增加以及对寡核甘酸业务的投资增加等因素，市场将在预测期内增长。预计将得到推动.

寡核甘酸合成市场竞争者分析

市场是分散的，许多公司采用各种策略（例如收购、销售合作伙伴关係和协作）在新兴市场开发新技术。 从事寡核甘酸合成行业的公司也在扩大和开发他们的产品组合，这正在推动整个市场，使其成为一个竞争激烈的市场。 目前主导市场的公司包括 Agilent Technologies、Thermo Fisher Scientific、Merck KGaA、Danaher Corporation、Bio-Synthesis Inc、Eurofins Scientific、Kaneka Corporation (Eurogentec)、GenScript 和 LGC Limited (LGC Biosearch Technologies)。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 调查先决条件和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 政府对製药和生物技术公司的投资和研发支出增加
    • 合成寡核甘酸在分子诊断和临床应用中的用途
  • 市场製约因素
    • 寡核甘酸的高治疗成本
    • 欠发达国家缺乏熟练的专业人员和研究支持
  • 行业吸引力 - 五力分析分析
    • 新进入者的威胁
    • 买家的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按产品类型
    • 合成寡核甘酸
    • 试剂
    • 设备
    • 服务
  • 通过使用
    • 调查研究
    • 诊断
    • 治疗药物
  • 最终用户
    • 学术研究所
    • 製药和生物技术公司
    • 医院和诊断机构
  • 按地区细分
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Agilent Technologies
    • Thermo Fisher Scientific
    • Merck KGaA
    • Danaher Corporation
    • Bio-Synthesis Inc.
    • Eurofins Scientific
    • Kaneka Corporation（Eurogentec）
    • GenScript
    • LGC Limited（LGC Biosearch Technologies）
    • Maravai Life Sciences
    • Biogen
    • Sarepta Therapeutics, Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 60475

The oligonucleotide synthesis market is expected to register a CAGR of 12.3% over the forecast period.

COVID-19 has impacted the growth of the oligonucleotide synthesis market. The increased demand for COVID-19 diagnostics has, in turn, increased the global demand for oligonucleotide raw materials that form the basis of molecular diagnostic products. In a study published in PLOS One in March 2022, it was observed that the oligonucleotides successfully targetted 5'-polyUs in the coronavirus genome. Also, developing therapeutic COVID-19 medicines employing essential mutational targets, such as the 5'-polyU tract, can lessen the production and spread of new SARS-CoV-2. Such research studies have impacted the demand and adoption for oligonucleotides in drug development, affecting the market growth during a pandemic.

Moreover, various companies are investing in oligonucleotide synthesis, which is expected to increase market growth over the forecast period. For instance, in September 2021, SpeeDx invested in local oligonucleotide manufacturing to reduce supply chain risk and develop a more vital sovereign capacity for critical diagnostics. Such developments are expected to increase the adoption of oligonucleotides in drug development which is anticipated to fuel the market growth over the forecast period.

Other significant factors include the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.

There are growing government initiatives for raising funds to develop various genome projects to develop advanced therapeutics to treat multiple chronic and rare diseases. This is expected to increase the demand for oligonucleotides for drug development, boosting the market growth. For instance, in September 2022, the National Institutes of Health invested more than USD 600 million to launch the next stage of its human genome project for the brain. This funding helps to devise new ways to target therapeutics and other molecules to specific brain cell populations.

Additionally, the rising company and government initiatives to boost the development of oligonucleotide-based drug products and the adoption of oligonucleotide technology in the pharmaceutical and biotechnology industry are also expected to increase market growth. For instance, in February 2021, CPI launched a project in the Medicines Manufacturing Innovation Centre to revolutionize the manufacture of oligonucleotides. The Medicines Manufacturing Innovation Centre launched a collaboration with AstraZeneca, Exactmer, Novartis, and UK Research and Innovation to develop a scalable, sustainable, and more cost-effective medicines manufacturing process for oligonucleotides: short strands of synthetic DNA or RNA. This development enhances the production capacity and viability of this exciting new class of medicines and is expected to increase market growth over the forecast period.

Furthermore, the increasing adoption of oligonucleotides in molecular diagnostics and clinical applications contributes to market growth. For instance, in February 2022, researchers at the University of Illinois Urbana developed a new miRNA point-of-care test for cancer detection. The test uses nanoparticles to capture tumor-specific microRNAs (miRNAs) in human serum. In January 2021, Diagenode launched a new small RNA-sequencing solution, D-Plex Small RNA DNBSEQ Kit, compatible with MGI's DNBSEQ sequencers. The kit incorporates unique D-Plex technology for library preparation enabling high performance with ultralow RNA inputs and providing diverse small RNA transcript detection.

Therefore, the studied market is expected to grow over the forecast period owing to the increasing research and development initiatives and the establishment of the facilities. However, the high treatment cost of oligonucleotides and the lack of skilled professionals and research support in undeveloped countries are expected to hinder the growth of the oligonucleotide synthesis market over the forecast period.

Oligonucleotide Synthesis Market Trends

Therapeutic Segment Expected to Register a High CAGR

The therapeutics segment is expected to witness significant growth in the oligonucleotide synthesis market over the forecast period owing to factors such as the increasing prevalence of chronic and rare diseases, along with the growing adoption of oligonucleotides in drug development and rising product launches.

Oligonucleotide therapeutics are classified as therapeutics that use antisense oligonucleotides or small interfering RNAs (siRNAs) to target RNA or protein. Oligonucleotide therapies include decoys that prevent transcription by concentrating on transcription factors, regulate the expression of complementary microRNA (miRNA) to specific mRNAs, and limit the translation of certain proteins from mRNA. For instance, as per an article published in Future Medicine in February 2022, oligonucleotide therapeutics is one of the most adaptable platforms for creating medications for rare diseases.

The growing company's focus on adopting various business strategies, such as collaborations, financing, and others, is also contributing to the market growth. For instance, in January 2022, Ceptur Therapeutics, Inc. successfully acquired USD 75 million in a Series-A financing round led by venBio Partners and Qiming Venture Partners USA to advance RNA therapeutics based on proprietary U1 adaptor technology, a bivalent oligonucleotide that engages sequence-specific mRNA and U1 small nuclear ribonuclear protein. The U1 small nuclear ribonuclear protein is a ubiquitous intracellular machine that regulates transcription and splicing. Utilizing synthetic oligonucleotides that interact with U1 snRNP offers the ability to co-opt the key transcriptome regulator to regulate mRNA in a highly targeted manner.

Furthermore, increasing product launches and approvals are expected to increase the demand for oligonucleotide drugs, propelling the market growth. For instance, in February 2021, the USFDA approved an Amondys 45 (casimersen) injection to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene.

Moreover, various companies are developing oligonucleotide therapeutics, which are expected to increase their adoption in the pharmaceutical and biotechnology industry, bolstering the market growth. For instance, as per clinicaltrials.gov, as of July 2022, TME Therapeutics is developing STNM01, which is being evaluated in a Phase-I clinical study to treat unresectable pancreatic cancer. Also, Nitto Biopharma is developing ND-L02-s0201 under a Phase-II study and is being assessed for idiopathic pulmonary fibrosis (IPF).

Therefore, owing to the factors such as the increasing company activities in adopting various business strategies for developing oligonucleotide-based drugs and rising product launches, the studied segment is anticipated to witness growth over the forecast period.

North America Expected to Occupy a Significant Share in the Studied Market

North America is expected to dominate the market over the forecast period. The factors attributing to the market growth are the rising prevalence of chronic and rare diseases among the population, increasing R&D expenditure by the companies, and the presence of key market players in the region.

According to the Cancer Facts and Figures 2022, over 1.9 million new cancer cases are expected to be diagnosed in the United States in 2022. Also, as per 2022 statistics published by Breastcancer.org, an estimated 287,850 new cases of invasive breast cancer and 51,400 new cases of non-invasive (in situ) breast cancer are expected to be diagnosed in the United States in 2022. The growing burden of cancer among the population raises the need for advanced therapeutics, boosting the demand for oligonucleotide therapeutics and propelling the market growth.

As per the 2022 statistics published by IDF, about 2.9 million people were living with diabetes in Canada in 2021. This number is projected to reach 3.2 million and 3.4 million by 2030 and 2045, respectively. Thus, the expected increase in the diabetic population in the country raises the demand for antisense oligonucleotides in developing antidiabetic agents, as they can reduce the expression of disease-causing genes at the RNA and protein levels. This is anticipated to boost the market growth over the forecast period,

The increasing development of drugs and rising regional product launches are anticipated to fuel market growth. For instance, in January 2022, the USFDA approved inclusion injection (Leqvio), an innovative small inclisiran RNA medicine, to be used with diet and statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Furthermore, as per clinicaltrials.gov, as of July 2022, TME Pharma Agis is conducting a Phase II clinical study of Olaptesed Pegol (NOX-A12) combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Moreover, the increasing investment by the companies to boost the production of oligonucleotide drugs and facility expansion is contributing to the market growth. For instance, in March 2021, Nitto Denko Corporation revealed its plan to invest about JPY 25 billion (USD 227 million) in its United States-based subsidiary, Nitto Denko Avecia Inc., and other businesses to increase the manufacturing capacity of its therapeutic oligonucleotide business.

Therefore, owing to the factors such as the rising burden of cancer, rising product launches and approvals, growing company activities in conducting clinical trials as well, and increasing company focus on investing in oligonucleotides business are anticipated to fuel the market growth in the North America region over the forecast period.

Oligonucleotide Synthesis Market Competitor Analysis

The market is fragmented with the presence of a large number of players adopting various strategies, such as the acquisition of players in emerging markets, distribution partnerships, and collaboration for the development of novel technologies. The companies operating in the oligonucleotide synthesis industry are also expanding and developing their product portfolios, which helps drive the overall market and makes it fairly competitive. Some of the companies which are currently dominating the market are Agilent Technologies, Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Bio-Synthesis Inc., Eurofins Scientific, Kaneka Corporation (Eurogentec), GenScript, and LGC Limited (LGC Biosearch Technologies).

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies
    • 4.2.2 The Use of Synthesized Oligonucleotides in Molecular Diagnostics and Clinical Applications
  • 4.3 Market Restraints
    • 4.3.1 High Treatment Cost of Oligonucleotides
    • 4.3.2 Lack of Skilled Professionals and Research Support in Undeveloped Countries
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Synthesized Oligonucleotide Products
    • 5.1.2 Reagents
    • 5.1.3 Equipment
    • 5.1.4 Services
  • 5.2 By Application
    • 5.2.1 Research
    • 5.2.2 Diagnostics
    • 5.2.3 Therapeutics
  • 5.3 By End-user
    • 5.3.1 Academic Research Institutes
    • 5.3.2 Pharmaceutical and Biotechnology Companies
    • 5.3.3 Hospital and Diagnostic Laboratories
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Thermo Fisher Scientific
    • 6.1.3 Merck KGaA
    • 6.1.4 Danaher Corporation
    • 6.1.5 Bio-Synthesis Inc.
    • 6.1.6 Eurofins Scientific
    • 6.1.7 Kaneka Corporation (Eurogentec)
    • 6.1.8 GenScript
    • 6.1.9 LGC Limited (LGC Biosearch Technologies)
    • 6.1.10 Maravai Life Sciences
    • 6.1.11 Biogen
    • 6.1.12 Sarepta Therapeutics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS